CRISPR and Fanzor in sickle cell disease: current progress and future prospects
Frontiers in Genome Editing · 26.05.2026 · 8
DOI: 10.3389/fgeed.2026.1774014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Genome Editing, online erschienen am 26.05.2026. Verfasst von Aisha Yousef Alhumoudi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Applied Genomics Technologies Institute, Health Sector, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia. Die Arbeit nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Advancements in genome editing have established a new frontier for the treatment of various genetic diseases, including sickle cell disease (SCD). SCD, the most prevalent monogenic blood disorder, causes severe pain, organ damage, and reduced life expectancy. The recent clinical approval of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-based gene therapies for severe sickle cell anemia marks a significant milestone in treating genetic diseases. Despite these breakthroughs, limitations in CRISPR technology persist, requiring further innovation. Alternative approaches, such as the Fanzor (Fz) system, are being developed to complement CRISPR’s capabilities. Unlike CRISPR, which is typically encoded within prokaryotic organisms, Fz is encoded in the eukaryotic genome, offering a universal RNA-guided mechanism applicable across all life kingdoms. Fz’s eukaryotic origin may facilitate more efficient delivery across diverse cell types and tissues, enhancing its therapeutic potential. Here, we will review the current successes and limitations of the CRISPR technology in editing mutation associated with SCD. Additionally, we will explore the potential role of Fz as a genome-editing tool for SCD, a field where its application has not yet been studied.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Applied Genomics Technologies Institute, Health Sector, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.
- Department of Biotechnology Evaluation and Development National Livestock and Fisheries Development Program, Riyadh, Saudi Arabia.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
- Digital Health Institute, Health Sector, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.
Zitieren
APA
Alhumoudi, A. Y., Alotaibi, A. G., Alosaimi, N. F., Alshalani, A., Alqahtani, S. M., Alsaab, S. M., Almutiri, B. J., & Albariqi, M. M. H. (2026). CRISPR and Fanzor in sickle cell disease: current progress and future prospects. Frontiers in Genome Editing, 8. https://doi.org/10.3389/fgeed.2026.1774014
Vancouver
Alhumoudi AY, Alotaibi AG, Alosaimi NF, Alshalani A, Alqahtani SM, Alsaab SM, et al. CRISPR and Fanzor in sickle cell disease: current progress and future prospects. Frontiers in Genome Editing. 2026;8. doi:10.3389/fgeed.2026.1774014
BibTeX
@article{Alhumoudi2026,
author = {Alhumoudi, Aisha Yousef and Alotaibi, Aminah Ghazi and Alosaimi, Nada Fahad and Alshalani, Abdulrahman and Alqahtani, Saad M and Alsaab, Sarah M and Almutiri, Basem Jahz and Albariqi, Mohammed M H},
title = {CRISPR and Fanzor in sickle cell disease: current progress and future prospects},
journal = {Frontiers in Genome Editing},
year = {2026},
volume = {8},
doi = {10.3389/fgeed.2026.1774014}
}
EUVIMED